Nuclear Medicine and Biology
Volume 35, Issue 1 , Pages 35-42 , January 2008

Evaluation of [11C]rofecoxib as PET tracer for cyclooxygenase 2 overexpression in rat models of inflammation

Received 29 June 2007 ,Revised 27 July 2007 ,Accepted 30 July 2007.

References 

  1. Katori M, Majima M. Cyclooxygenase-2: its rich diversity of roles and possible application of its selective inhibitors. Inflamm Res. 2000;49:367–392
  2. Tzeng SF, Hsiao HY, Mak OT. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Curr Drug Targets Inflamm Allergy. 2005;4:335–340
  3. Yermakova A, O'Banion MK. Cyclooxygenases in the central nervous system: implications for treatment of neurological disorders. Curr Pharm Des. 2000;6:1755–1776
  4. Learn CA, Mizel SB, McCall CE. mRNA and protein stability regulate the differential expression of pro- and anti-inflammatory genes in endotoxin-tolerant THP-1 cells. J Biol Chem. 2000;275:12185–12193
  5. Lukiw WJ, Bazan NG. Cyclooxygenase 2 RNA message abundance, stability, and hypervariability in sporadic Alzheimer neocortex. J Neurosci Res. 1997;50:937–945
  6. De Vries EFJ. Imaging of Cyclooxygenase-2 (COX-2) expression: potential use in diagnosis and drug evaluation. Curr Pharm Des. 2006;12:3847–3856
  7. Pairet M, van Ryn J. Experimental models used to investigate the differential inhibition of cyclooxygenase-1 and cyclooxygenase-2 by non-steroidal anti-inflammatory drugs. Inflamm Res. 1998;47(Suppl 2):S93–S101
  8. McCarthy TJ, Sheriff AU, Graneto MJ, Talley JJ, Welch MJ. Radiosynthesis, in vitro validation, and in vivo evaluation of 18F-labeled COX-1 and COX-2 inhibitors. J Nucl Med. 2002;43:117–124
  9. De Vries EFJ, van Waarde A, Buursma AR, Vaalburg W. Synthesis and in vivo evaluation of 18F-desbromo-DuP-697 as a PET tracer for cyclooxygenase-2 expression. J Nucl Med. 2003;44:1700–1706
  10. Majo VJ, Prabhakaran J, Simpson NR, Van Heertum RL, Mann JJ, Kumar JS. A general method for the synthesis of aryl [11C]methylsulfones: potential PET probes for imaging cyclooxygenase-2 expression. Bioorg Med Chem Lett. 2005;15:4268–4271
  11. Wust FR, Hohne A, Metz P. Synthesis of 18F-labelled cyclooxygenase-2 (COX-2) inhibitors via Stille reaction with 4-[18F]fluoroiodobenzene as radiotracers for positron emission tomography (PET). Org Biomol Chem. 2005;3:503–507
  12. Prabhakaran J, Majo VJ, Simpson NR, Van Heertum RL, Mann JJ, Kumar JSD. Synthesis of [C-11]celecoxib: a potential PET probe for imaging COX-2 expression. J Label Compd Radiopharm. 2005;48:887–895
  13. Ahuja N, Singh A, Singh B. Rofecoxib: an update on physicochemical, pharmaceutical, pharmacodynamic and pharmacokinetic aspects. J Pharm Pharmacol. 2003;55:859–894
  14. Halpin RA, Geer LA, Zhang KE, Marks TM, Dean DC, Jones AN, et al. The absorption, distribution, metabolism and excretion of rofecoxib, a potent and selective cyclooxygenase-2 inhibitor, in rats and dogs. Drug Metab Dispos. 2000;28:1244–1254
  15. Larsen P, Ulin J, Dahlstrom K, Jensen M. Synthesis of [C-11]iodomethane by iodination of [C-11]methane. Appl Radiat Isot. 1997;48:153–157
  16. Buursma AR, De Vries EFJ, Garssen J, Kegler D, van Waarde A, Schirm J, et al. [18F]FHPG positron emission tomography for detection of herpes simplex virus (HSV) in experimental HSV encephalitis. J Virol. 2005;79:7721–7727
  17. Lacroix S, Rivest S. Effect of acute systemic inflammatory response and cytokines on the transcription of the genes encoding cyclooxygenase enzymes (COX-1 and COX-2) in the rat brain. J Neurochem. 1998;70:452–466
  18. Quan N, Whiteside M, Herkenham M. Cyclooxygenase 2 mRNA expression in rat brain after peripheral injection of lipopolysaccharide. Brain Res. 1998;802:189–197
  19. Doorduin J, De Vries EFJ, Dierckx RA, Klein HC. PET imaging of herpes simplex encephalitis in rats. J Label Compd Radiopharm. 2007;50(Suppl 1):S60
  20. Dembo G, Park SB, Kharasch ED. Central nervous system concentrations of cyclooxygenase-2 inhibitors in humans. Anesthesiology. 2005;102:409–415
  21. Yamada S, Kubota K, Kubota R, Ido T, Tamahashi N. High accumulation of fluorine-18-fluorodeoxyglucose in turpentine-induced inflammatory tissue. J Nucl Med. 1995;36:1301–1306
  22. van Waarde A, Cobben DC, Suurmeijer AJ, Maas B, Vaalburg W, De Vries EFJ, et al. Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model. J Nucl Med. 2004;45:695–700
  23. Kimura T, Iwase M, Kondo G, Watanabe H, Ohashi M, Ito D, et al. Suppressive effect of selective cyclooxygenase-2 inhibitor on cytokine release in human neutrophils. Int Immunopharmacol. 2003;3:1519–1528
  24. Kumagai T, Matsukawa N, Kaneko Y, Kusumi Y, Mitsumata M, Uchida K. A lipid peroxidation-derived inflammatory mediator: identification of 4-hydroxy-2-nonenal as a potential inducer of cyclooxygenase-2 in macrophages. J Biol Chem. 2004;279:48389–48396
  25. Copeland RA, Williams JM, Giannaras J, Nurnberg S, Covington M, Pinto D, et al. Mechanism of selective inhibition of the inducible isoform of prostaglandin G/H synthase. Proc Natl Acad Sci U S A. 1994;91:11202–11206

PII: S0969-8051(07)00215-6

doi: 10.1016/j.nucmedbio.2007.07.015

Nuclear Medicine and Biology
Volume 35, Issue 1 , Pages 35-42 , January 2008

Article Tools

* Image Usage & Resolution